Company Profile
Nkarta Stock Price, News & Catalysts
- Ticker:
- NKTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.12 USD (-2.61%)
Close
Last updated: November 19, 2026
208M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, NKTX closed down 2.61% at $1.12. No new same-company headline was identified in the current news window.
Company overview
Allogeneic CAR-NK Company
Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
NKX019
NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing.
Ntrust Studies
Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the option for redosing.
Off-the-Shelf Treatment Model
Nkarta manufactures cryopreserved cell therapy in advance rather than creating a bespoke product for each patient. The model is intended to support outpatient administration, repeat dosing and broader treatment-center access.
Future catalysts
- Initial NKX019 clinical data in idiopathic inflammatory myopathy and systemic sclerosis at ACR Convergence 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nkarta (NKTX)?
Nkarta (NKTX) most recently closed at 1.12 USD, a -2.61% move versus the previous session.
What is the market cap of Nkarta (NKTX)?
Nkarta currently has a market capitalization of 208M USD on BioPharmSignal.
What does Nkarta do?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the...
On which exchange is NKTX stock listed?
Nkarta (NKTX) is associated with NASDAQ, United States, Biopharma.
What is CAR-NK?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
Which conditions is Nkarta targeting with CAR-NK?
Nkarta is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Nkarta describe recent progress with CAR-NK?
Initial NKX019 clinical data in idiopathic inflammatory myopathy and systemic sclerosis at ACR Convergence 2026.
What is Allogeneic?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
